Clearmind Medicine Inc. (CMND)
After hours:
| Previous close | 1.4700 |
| Open | 1.3600 |
| Bid | 1.4600 x 100 |
| Ask | 1.5300 x 100 |
| Day's range | 1.3510 - 1.5300 |
| 52-week range | 0.9210 - 23.7000 |
| Volume | |
| Avg. volume | 1,298,663 |
| Market cap | 4.892M |
| Beta (5Y monthly) | -1.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.8900 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireClearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
Vancouver, Canada, May 07, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces the signing of an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement provides Clearmind with exclusive global right
- GlobeNewswire
Clearmind Applies to Cease Being a Reporting Issuer in Canada
Vancouver, Canada, April 30, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWYO) ("Clearmind" or the “Company”), a clinical- stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it will apply to the British Columbia Securities Commission (the “BCSC”), as principal regulator, the Ontario Securities Commission (the "OSC"), as non-principal regulator, and
GlobeNewswireClearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This partnership marks a significant step in harnessing generation 3.0
